Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Safety Study of Intratumorally Administered INT230-6 in Adult Subjects With Advanced Refractory Cancers

Next Previous
Trial Profile

A Phase 1/2 Safety Study of Intratumorally Administered INT230-6 in Adult Subjects With Advanced Refractory Cancers

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 14 Dec 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cisplatin/vinblastine (Primary) ; Ipilimumab (Primary) ; Pembrolizumab (Primary)
  • Indications Advanced breast cancer; Carcinoma; Cholangiocarcinoma; Chondrosarcoma; Chordoma; Colon cancer; Colorectal cancer; Head and neck cancer; Leiomyosarcoma; Liposarcoma; Liver cancer; Lung cancer; Lymphoma; Malignant melanoma; Pancreatic cancer; Sarcoma; Skin cancer; Soft tissue sarcoma; Solid tumours; Squamous cell cancer; Triple negative breast cancer
  • Focus Adverse reactions
  • Acronyms INTENSITY-IT-01; IT-01; KEYNOTE A10
  • Sponsors Intensity Therapeutics

Most Recent Events

  • 18 Nov 2024 According to an Intensity Therapeutics media release, company presented final safety and efficacy data from this trial during an oral podium presentation in a late-breaking session at the 2024 Connective Tissue Oncology Society ("CTOS") on November 16, 2024, at 9 AM PST.
  • 18 Nov 2024 Results published in an Intensity Therapeutics Media Release.
  • 02 Nov 2023 Results published in an Intensity Therapeutics Media Release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top